Recent studies have shown that inhibitors of the sodium-glucose transporter 2 (SGLT2) that were developed for diabetes are also effective in reducing cardiovascular death and hospitalizations in patients with HFpEF32. The gene discussed is SLC5A2; the disease is diabetes mellitus.